Related Experiment Video
Updated: Jun 27, 2026
Carotid Artery Infusions for Pharmacokinetic and Pharmacodynamic Analysis of Taxanes in Mice
Published on: October 27, 2014
Safety of nab-paclitaxel plus sunitinib: analysis of three cases
Arkadiusz Z Dudek1, Sheila Nguyen
1Division of Hematology, Oncology and Transplantation, University of Minnesota, Minneapolis, MN 55455, USA. dudek002@umn.edu
Background:
Second-line treatment options are limited in controlling advanced thoracic cancer in patients who have progressed following first-line chemotherapy.
Case Report:
The safety of combination therapy with nab-paclitaxel, an albumin-bound paclitaxel, and sunitinib, a tyrosine kinase receptor inhibitor, was evaluated retrospectively in three patients with advanced, previously treated metastatic esophageal cancer, non-small cell lung cancer (NSCLC), and small cell lung cancer (SCLC), respectively.
Results:
Grade 3 and 4 toxicities were mainly hematological and manageable. A notable improvement in cancer symptoms and reduction in tumor size were seen in all three patients.
Conclusion:
Based on the easily managed toxicities and apparent efficacy of the regimen of weekly nab-paclitaxel and daily sunitinib, we conclude that further evaluation is warranted to assess the efficacy of this combination therapy in previously chemotherapy-treated patients with advanced thoracic cancer.
